Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy
The Hoxb8 MAT demonstrated a very good diagnostic precision in patients prospectively assessed for peanut allergy comparable to the fresh whole blood-based BAT. Additionally, it demonstrated its value for accurate classification of BAT nonresponders into allergic and nonallergic individuals. Further investigations into its utility in the routine clinical setting are warranted.
Authors
- Noemi Bachmeier‐Zbären
- Robin van Brummelen (ORCID: https://orcid.org/0000-0003-1182-8519)
- Alper Çelik (ORCID: https://orcid.org/0000-0003-2084-5871)
- Thomas Eiwegger (ORCID: https://orcid.org/0000-0002-2914-7829)
- Christina M. Ditlof
- Lucy Duan (ORCID: https://orcid.org/0000-0002-0560-583X)
- Thomas Kaufmann (ORCID: https://orcid.org/0000-0001-9906-874X)
- Alexander Eggel (ORCID: https://orcid.org/0000-0001-8746-3339)
- Julia Upton (ORCID: https://orcid.org/0000-0001-5320-4232)
- Jennifer A. Hoang (ORCID: https://orcid.org/0000-0001-9264-1881)
- Xiaojun Yin (ORCID: https://orcid.org/0000-0002-5925-297X)
- Nadine Roos
- Melanie Steinmann
Institutions
- University of Bern (CH)
- University of Toronto (CA)
- University of Applied Sciences St Pölten (AT)
- University Hospital of Bern (CH)
- Hospital for Sick Children (CA)
- Karl Landsteiner University of Health Sciences (AT)
Publication Details
- Journal
- Allergy
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1111/all.16341
- Citations
- 14
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 5.36
Funders
- National Science Foundation
- Novartis
- Sanofi
- Danone
- Regeneron Pharmaceuticals
- European Food Safety Authority
- Aimmune Therapeutics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Austrian Science Fund
- Hospital for Sick Children
- Innosuisse - Schweizerische Agentur für Innovationsförderung
- Bausch Health
- Food Allergy Canada
- Canadian Institutes of Health Research